MS: Busting the Myths
June 26, 2023 | Media, Progressive
Te Pātaka Whaioranga – Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) for the treatment of all […]
June 22, 2023 | Advocacy, Funding, Media, Progressive
Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]
July 26, 2022 | Life with MS, Progressive, Research
Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC […]
June 29, 2022 | Advocacy, Media
Listen to MSNZ President, Neil Woodhams talk with RNZ presenters on the afternoon show ‘The Panel’. Hear him discuss the impacts Pharmac’s revised criteria for people with MS accessing medication earlier than ever before will have on people with MS […]
June 16, 2022 | Advocacy, Life with MS, Treatments
Multiple Sclerosis NZ is pleased to see the announcement this week from Pharmac to provide access to funded MS treatments earlier than ever before. The new criteria will no longer require those clinically diagnosed with MS to wait for […]